Praktische Erfahrungen zur Verbesserung der Alltagskompetenz bei Parkinson-Patienten unter Therapie mit Ropinirol

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Der Nervenarzt

• Publication date

  2005-10-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s00115-005-1957-y
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Prevalence, etiology, and treatment of depression in Parkinson's disease.

  2003cited by this paper
• Physical anhedonia in Parkinson’s disease

  2003cited by this paper
• Randomized, double‐blind, 3‐month parallel study of the effects of pramipexole, pergolide, and placebo on parkinsonian tremor

  2003cited by this paper
• Impairments in activities of daily living in Parkinson's disease: Implications for management

  2003cited by this paper
• Apathy in Parkinson’s disease

  2002cited by this paper
• Ropinirole for the treatment of tremor in early Parkinson's disease

  2002cited by this paper
• Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes

  2002cited by this paper
• Dosing with ropinirole in a clinical setting

  2002cited by this paper
• A possible substrate for dopamine-related changes in mood and behavior: Prefrontal and limbic effects of a D3-preferring dopamine agonist

  2002cited by this paper
• Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series.

  2001cited by this paper
• A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

  2000cited by this paper
• Anxiolytic profile of ropinirole in the rat, mouse and common marmoset

  2000cited by this paper
• Linear Pharmacokinetic Behavior of Ropinirole during Multiple Dosing in Patients with Parkinson's Disease

  2000cited by this paper
• A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease

  1999cited by this paper
• The Safety of Ropinirole, a Selective Nonergoline Dopamine Agonist, in Patients with Parkinson's Disease

  1998cited by this paper
• Pharmacologic profile of ropinirole

  1997cited by this paper
• Ropinirole for the treatment of early Parkinson's disease

  1997cited by this paper
• Ropinirole in the symptomatic treatment of Parkinson's disease.

  1995cited by this paper

• Clinical evaluation of ropinirole controlled-release formulation at 18-24 mg/day in Japanese patients with Parkinson's disease.

  2017cites this paper
• The effect of Madopar on the pharmacokinetics of ropinirole in healthy Chinese volunteers.

  2007cites this paper
• Die Verbesserung motorischer und nicht-motorischer Symptome bei Parkinson-Patienten unter einer Therapie mit Ropinirol

  2007cites this paper